SpliceBio has raised $135M in Series B funding, led by EQT Life Sciences and Sanofi Ventures, to advance its lead gene therapy candidate for Stargardt disease.
Amount Raised
$135 Million
Round Type
Series B
BarcelonaBiotechnologySoftwareScience And EngineeringInvestors
Description
SpliceBio, a Barcelona-based clinical-stage genetic medicines company, raised $135M in Series B funding. The round was led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund and existing investors. The funds will support the clinical development of its gene therapy candidate SB-007 for Stargardt disease. Key investors will join the SpliceBio Board of Directors.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as SpliceBio that raised within 45 days of this round, from Fundz verified event records.
- Classiq raised $110M (Series C) on May 12, 2025.
- Aidoc raised $150M (Funding Round) on July 23, 2025.
- Zucca raised $5M (Seed) on July 17, 2025.
- Tomoverse Imaging raised $5M (Seed) on July 11, 2025.
- Gigged.Ai raised $1.4M (Seed) on July 10, 2025.
- Lab Thread raised $1M on July 8, 2025.
Who to call at SpliceBio, and when
A new round usually means SpliceBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day SpliceBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SpliceBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SpliceBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SpliceBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSpliceBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.